Telomir Pharmaceuticals Overview
Latest P/E ratio for Telomir Pharmaceuticals: -0.75 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-0.75
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for TELO is -0.75. That is below the sector sector average of 33.83. Investors often review this figure alongside Telomir Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, TELO currently prints -0.75 for P/E ratio, while the sector average sits near 33.83. That is roughly 102.2% below the sector mean. Large gaps often invite a closer look at Telomir Pharmaceuticals's growth, margins, and balance sheet.
A P/E ratio of -0.75 for Telomir Pharmaceuticals is not 'good' or 'bad' on its own. Compare it with the peer average (33.83) and with TELO's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting TELO's P/E ratio (-0.75), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
